Alector

ALECTOR INC

Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.

Brain,Degenerative,Diseases,Parkinson,,Alzheimer,,Puzzle

Analyst Color

Biotech

News

Downgrades

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

ABBV

ALEC

Alector&#39;s AL002 misses primary endpoint in Alzheimer&#39;s trial. BofA downgrades stock, cuts price target, and highlights near-term challenges.

Neurology-Focused Alector Downgraded On Failed Alzheimer&#39;s Study, BofA Securities Highlights Lack Of Catalysts

opec oil shutter

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

EMBC

HSAI

LESL

PSTX

Crude Oil Moves Lower; Dick&#39;s Sporting Goods Earnings Top Views

Philadelphia,,Pennsylvania,,May,19,2018:,Abercrombie,&amp;,Fitch,Clothing,Store

Nasdaq Rises 100 Points; Abercrombie &amp; Fitch Shares Fall After Q3 Results

Alector Inc

Press Releases

Alector to Participate in Upcoming Healthcare Conferences

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Financing

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Management

Alector Provides Executive Leadership Update

HTGC

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

C4 Therapeutics

Coherus BioSciences

Cellectis S.A. - American Depositary Shares

Cellectis

Climb Bio

Coya Therapeutics

CervoMed

Elutia

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

Immunic

Kodiak Sciences

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Seres Therapeutics

Neurogene

Nkarta

Regulus Therapeutics

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

SELLAS Life Sciences Group, Inc. - Common Stock

SELLAS Life Sciences Gr

Instil Bio

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

XBiotech

Morgan Stanley

HC Wainwright & Co.

Stifel

BTIG

Comments

Alector

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga